Pathogenesis and Prevention of Hepatic Steatosis.
暂无分享,去创建一个
F. Nassir | R. Rector | G. Hammoud | J. Ibdah | R Scott Rector | Jamal A Ibdah | Fatiha Nassir | Ghassan M Hammoud
[1] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[2] G. Musso,et al. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). , 2009, Progress in lipid research.
[3] William O Richards,et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. , 2010, Gastroenterology.
[4] R. Rector,et al. Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats. , 2014, Journal of applied physiology.
[5] Jian-Gao Fan,et al. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.
[6] J. Friedman,et al. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] R. Rector,et al. Metabolic inflexibility in skeletal muscle: a prelude to the cardiometabolic syndrome? , 2006, Journal of the cardiometabolic syndrome.
[8] F. Booth,et al. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[9] M. Ristow,et al. Mitochondria and metabolic homeostasis. , 2013, Antioxidants & redox signaling.
[10] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[11] S. Bellentani,et al. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). , 2009, Annals of hepatology.
[12] S. Taylor-Robinson,et al. Non-invasive means of measuring hepatic fat content. , 2008, World journal of gastroenterology.
[13] McGinnis Jm,et al. Actual causes of death in the United States. , 1993 .
[14] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[15] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[16] F. Nassir,et al. Role of Mitochondria in Nonalcoholic Fatty Liver Disease , 2014, International journal of molecular sciences.
[17] T. Moran,et al. Running wheel activity prevents hyperphagia and obesity in Otsuka long-evans Tokushima Fatty rats: role of hypothalamic signaling. , 2005, Endocrinology.
[18] J. Dyck,et al. Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity , 2007, Diabetes.
[19] J. Stern,et al. Spontaneous activity and adipose cellularity in the genetically obese Zucker rat (fafa). , 1977, Metabolism: clinical and experimental.
[20] Frank W. Booth,et al. Reduced physical activity and risk of chronic disease: the biology behind the consequences , 2008, European Journal of Applied Physiology.
[21] Leah Hennings,et al. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[22] J. Sallis,et al. Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease , 2011, The American Journal of Gastroenterology.
[23] J. Browning,et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.
[24] J. Gerberding,et al. Actual causes of death in the United States, 2000. , 2004, JAMA.
[25] M. Yeh,et al. The biopsied donor liver: Incorporating macrosteatosis into high‐risk donor assessment , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[26] E. Ferrannini,et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.
[27] J. Lavoie,et al. Effects of ingesting a high-fat diet upon exercise-training cessation on fat accretion in the liver and adipose tissue of rats. , 2006, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[28] A. Hamsten,et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. , 2007, The Journal of clinical endocrinology and metabolism.
[29] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[30] S. Caldwell,et al. The Natural History of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.
[31] F. Booth,et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. , 2010, Journal of Hepatology.
[32] B. S. Mohammed,et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.
[33] F. Booth,et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[34] A. Häkkinen,et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.
[35] Z. Yao,et al. ReviewRecent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion , 2010 .
[36] F. Booth,et al. Lack of exercise is a major cause of chronic diseases. , 2012, Comprehensive Physiology.
[37] H. Ohdan,et al. Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery , 2014, Surgery Today.
[38] J. Burnett,et al. Genetic determinants of hepatic steatosis in man , 2011, Journal of Lipid Research.
[39] F. Nassir,et al. CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice[S] , 2013, Journal of Lipid Research.
[40] S. Sookoian,et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation of the peroxisome proliferator–activated receptor γ coactivator 1α promoter , 2010, Hepatology.
[41] M. Hellerstein,et al. Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans Published, JLR Papers in Press, August 23, 2006. , 2006, Journal of Lipid Research.
[42] S. Bellentani,et al. Hepatology Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) , 2009 .
[43] J. Joh,et al. Impact of hepatic macrovesicular and microvesicular steatosis on the postoperative liver functions after right hepatectomy in living donors. , 2012, Transplantation Proceedings.
[44] F. Booth,et al. Hepatic steatosis development with four weeks of physical inactivity in previously active, hyperphagic OLETF rats. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.
[45] M. Beylot,et al. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. , 2003, Diabetes & metabolism.
[46] O. Chazouilleres,et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C , 2005, Hepatology.
[47] J. Schulz-Menger,et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects , 2011, Hepatology.
[48] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[49] L. Adams,et al. Recent concepts in non‐alcoholic fatty liver disease , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[50] B. S. Mohammed,et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.
[51] R. Rector,et al. Does physical inactivity cause nonalcoholic fatty liver disease? , 2011, Journal of applied physiology.
[52] Yoshimasa Kusano,et al. Prevalence of fatty liver in Japanese children and relationship to obesity , 1995, Digestive Diseases and Sciences.
[53] J. Kaprio,et al. Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins , 2007, The Journal of physiology.
[54] T. Muto,et al. Regular physical activity and coronary risk factors in Japanese men. , 1998, Circulation.
[55] Z. Halpern,et al. Role of leisure‐time physical activity in nonalcoholic fatty liver disease: A population‐based study , 2008, Hepatology.
[56] S. Harrison,et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.
[57] D. Lobo,et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. , 2004, Journal of hepatology.
[58] A. Lonardo,et al. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. , 1996, Gastroenterology.
[59] J. González‐Gallego,et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C , 2011, Gut.
[60] G. O. Lignac. [Actual causes of death]. , 1951, Nederlands tijdschrift voor geneeskunde.
[61] F. Welty. Hypobetalipoproteinemia and abetalipoproteinemia , 2014, Current opinion in lipidology.
[62] J. Schwarz,et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. , 2003, The American journal of clinical nutrition.
[63] J. Hirsch,et al. Human fatty acid synthesis is reduced after the substitution of dietary starch for sugar. , 1998, The American journal of clinical nutrition.
[64] A. Ascensão,et al. Modulation of hepatic redox status and mitochondrial metabolism by exercise: therapeutic strategy for liver diseases. , 2013, Mitochondrion.
[65] E. Hoffman,et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. , 2005, Cell metabolism.
[66] Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing[S] , 2012, Journal of Lipid Research.
[67] M. Connelly,et al. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. , 2011, Human molecular genetics.
[68] S. Burgess,et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. , 2011, Cell metabolism.
[69] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.
[70] Gustav Schonfeld,et al. Familial hypobetalipoproteinemia Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R300002-JLR200 , 2003, Journal of Lipid Research.
[71] J. Barkin. The Natural History of Nonalcoholic Fatty Liver Disease: A Population Based Cohort Study , 2006 .
[72] B. Atshaves,et al. Decreased Liver Fatty Acid Binding Capacity and Altered Liver Lipid Distribution in Mice Lacking the Liver Fatty Acid-binding Protein Gene* , 2003, Journal of Biological Chemistry.
[73] S. Kennedy,et al. Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice , 2006, Hepatology.
[74] M. Nystrom,et al. MRI steatosis grading: development and initial validation of a color mapping system. , 2012, AJR. American journal of roentgenology.
[75] T. Lehtimäki,et al. Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. , 2011, Journal of hepatology.
[76] P. Blackman. Actual causes of death in the United States. , 1994, JAMA.
[77] B. Neuschwander‐Tetri. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.
[78] R. Rector,et al. Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction. , 2012, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[79] J. Dyck,et al. Increased Hepatic CD 36 Expression Contributes to Dyslipidemia Associated with Diet-Induced Obesity , 2007 .
[80] B. S. Mohammed,et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.
[81] J. Cline,et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. , 2005, Gastroenterology.
[82] F. Booth,et al. Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. , 2014, American journal of physiology. Endocrinology and metabolism.
[83] L. Mâsse,et al. Physical activity in the United States measured by accelerometer. , 2008, Medicine and science in sports and exercise.
[84] Olga Ilkayeva,et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.
[85] F. Nassir,et al. Role of mitochondria in alcoholic liver disease. , 2014, World journal of gastroenterology.
[86] R. Ross,et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. , 2006, Gastroenterology.
[87] N. Enomoto,et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[88] D. Reeds,et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.
[89] Amalia Gastaldelli,et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.
[90] J. George,et al. Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease , 2010, Hepatology.
[91] Chiadi E. Ndumele,et al. Hepatic Steatosis, Obesity, and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[92] D. Harnois. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011 .
[93] R. Gimeno,et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. , 2006, Gastroenterology.
[94] Jiayin Yang,et al. Impact of graft steatosis on the post-transplantation biliary complications for living donor liver transplant recipients in China. , 2012, Hepato-gastroenterology.
[95] J. Ibdah,et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. , 1999, The New England journal of medicine.
[96] Theresa A. Storm,et al. Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia* , 2008, Journal of Biological Chemistry.
[97] M. Kay,et al. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. , 2010, American journal of physiology. Endocrinology and metabolism.
[98] J. Friedman,et al. Developmental origins of nonalcoholic fatty liver disease , 2014, Pediatric Research.
[99] P. Nilsson,et al. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD , 2014, Scandinavian journal of gastroenterology.
[100] D. Gomez,et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis , 2007, The British journal of surgery.
[101] H. Kalbacher,et al. De novo lipogenesis in health and disease. , 2014, Metabolism: Clinical and Experimental.
[102] F. Hsu,et al. Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect , 2013, Hepatology.
[103] F. Spener,et al. Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. , 1999, Biochimica et biophysica acta.
[104] N. Johnson,et al. Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders , 2012, Seminars in Liver Disease.
[105] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.